Merck (MRK) ended the recent trading session at $80.32, demonstrating a -1.27% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.27%.

An analyst's downbeat new take on Summit Therapeutics ( SMMT -11.32%) pushed its stock downward on Hump Day. At the end of ...

Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, ...

The stock's fall snapped a three-day winning streak.

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Merck scored a major win with FDA approval for Enflonsia, its fresh RSV-fighting antibody aimed at shielding infants. This ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...